{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-26-000050","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2026-09-22T11:08:26+00:00","discovered_at":"2026-09-22T11:10:00.273228+00:00","generated_at":"2026-09-22T11:10:25.359083+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ligand buys Santen's Ryjunea royalty rights for $23M upfront","bullets":["$23M upfront acquires 100% interest in tiered low-double-digit-to-high-teens royalty on Ryjunea EMEA net sales.","Ryjunea is EU/UK's first approved pharmacologic treatment to slow pediatric myopia; EC approved June 2025, UK MHRA Oct 2025.","Santen licensed EMEA rights from Sydnexis in 2021; Ligand steps into those payment rights; Sydnexis keeps US and other territories.","Market: ~14M myopia patients in Europe 2025; 1 in 3 children projected affected by 2050."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-26-000050","json":"https://secwatch.observer/filing/0000886163-26-000050.json","markdown":"https://secwatch.observer/filing/0000886163-26-000050.md","text":"https://secwatch.observer/filing/0000886163-26-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/0000886163-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616326000050/lgnd-20260922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-22T11:10:25.359083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}